22 results
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
adverse effect on Tenet’s business, results of operations, financial condition, and prospects.
Tenet may not have access to the raw materials and other
DEFM14A
ELYM
Eliem Therapeutics Inc
4 Jun 24
Proxy related to merger
8:00am
business, results of operations, financial condition, and prospects.
Tenet may not have access to the raw materials and other components necessary … our planned clinical trials, continue research and development activities, utilize third parties to manufacture drug products and related raw materials, hire
PREM14A
ELYM
Eliem Therapeutics Inc
17 May 24
Preliminary proxy related to merger
4:36pm
may not have access to the raw materials and other components necessary for the manufacturing of TNT119.
Tenet is dependent on third parties … commence our planned clinical trials, continue research and development activities, utilize third parties to manufacture drug products and related raw
10-K
a1ez2jmfeu6w
7 Mar 22
Annual report
4:03pm
10-Q
zhuws
13 Sep 21
Quarterly report
4:01pm
424B4
kpmru9zv8
11 Aug 21
Prospectus supplement with pricing info
5:05pm
S-1/A
88vaf rba1uba6g9vxs
2 Aug 21
IPO registration (amended)
6:08am
S-1
qh7z5j6iv89wuwxd
16 Jul 21
IPO registration
5:02pm
DRS/A
whd9zr
12 Jul 21
Draft registration statement (amended)
12:00am